1751 RIVER RUN, FORT WORTH, TX
Announces Pricing of $15.0 Million Public Offering of Common Stock
News, Securities Holder Rights or Indentures, Material Contracts
Transcript of Key Opinion Leader Event
Elraglusib Phase 2 Data Shows Promise in Pancreatic Cancer at ASCO 2025
Shareholder votes
Other Events
News, Material Contracts
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities